Haemonetics Corp. Stock
€46.00
Your prediction

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Haemonetics
sharewise wants to provide you with the best news and tools for Haemonetics, so we directly link to the best financial data sources.
Financials
News
Haemonetics Q4 Earnings Call Highlights
Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
Invenomic Capital Management fully exited its position in Haemonetics Corporation (NYSE:HAE), according to a February 17, 2026, SEC filing, selling 498,317 shares previously worth $24.29 million.


